PAREXEL International
United States
About PAREXEL International
520 articles about PAREXEL International
-
Parexel Named “Best Contract Research Organization” at 19th Annual Scrip Awards
11/17/2023
Parexel today announced today announced it has been named “Best Contract Research Organization” in the Full-Service Provider category at the 19th Annual Scrip Awards.
-
Parexel’s Amy McKee, M.D. Named to 2023 PharmaVoice 100
9/20/2023
Parexel, one of the world’s largest clinical research organizations providing the full range of Phase I to IV clinical development services, announced that Chief Medical Officer and Global Head, Oncology Center of Excellence, Amy McKee, M.D., has been named to the PharmaVoice 100 list of influential people in the life sciences industry.
-
Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and Development
8/15/2023
Parexel and Partex announced a preferred strategic alliance designed to leverage artificial intelligence -powered solutions to accelerate drug discovery and development for biopharmaceutical customers worldwide and de-risk the assets in their portfolios.
-
Parexel Announces Updates to Board of Directors
6/23/2023
Parexel today announced the appointments of Michael Bruun, Partner, Global co-Head of Private Equity, Goldman Sachs Asset Management, and John Groetelaars, Non-Executive Director and former Interim CEO of Dentsply Sirona and former President & CEO at Hillrom, to its Board of Directors.
-
Parexel Appoints Scott Smith, M.D., Ph.D. as New Head of Hematology
4/19/2023
Parexel today announced the appointment of Scott Smith, M.D., Ph.D. as Senior Vice President, Global Therapeutic Area Head – Hematology.
-
Parexel Opens Clinical Trial Supplies and Logistics Depot in Suzhou, China
9/27/2022
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the opening of a new clinical trial supplies and logistics depot in Suzhou, China.
-
Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence
9/14/2022
Parexel, a leading global clinical research organization, announced the promotions of Peyton Howell to the newly-created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence.
-
Parexel Expands Network of Global Regulatory Experts
9/8/2022
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the appointment of five former regulators to its Regulatory & Access Consulting team, further accelerating the advancement of new treatments for patients worldwide.
-
Addex Therapeutics announced it is canceling its Phase IIb/III study evaluating its drug dipraglurant due to patient recruiting, staffing and pandemic-related issues.
-
Parexel Bolsters Regulatory and Access Offering with Key Appointment
1/11/2022
Parexel announced the appointment of Wyatt Gotbetter as the company’s Head of Worldwide Access Consulting to lead all facets of this growing business with a focus on helping customers position products for market success.
-
EQT Private Equity and Goldman Sachs Asset Management Complete Acquisition of Parexel
11/15/2021
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the completion of its acquisition by EQT IX fund and funds managed by the Private Equity business within Goldman Sachs Asset Management from Pamplona Capital Management LP for $8.5 billion.
-
Parexel Strengthens Clinical Data and Digital Services Offering with Key Appointment
10/4/2021
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the appointment of Stephen Pyke as the company’s Executive Vice President, Clinical Data and Digital Services.
-
Parexel’s Peyton Howell and Sofia Baig Named to 2021 PharmaVOICE 100
8/2/2021
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced that two of its visionary leaders have been named to the PharmaVOICE 100 list of the most inspiring people in the life sciences industry.
-
Upon completion of the merger, Parexel will be owned by EQT IX Fund and the private equity business within Goldman Sachs Asset Management.
-
EQT Private Equity and Goldman Sachs Asset Management to acquire Parexel, a leading global clinical research organization, for USD 8.5 billion
7/2/2021
The EQT IX fund and the Private Equity business within Goldman Sachs Asset Management have agreed to acquire Parexel, a leading global clinical research organization from Pamplona Capital Management for an enterprise value of USD 8.5 billion.
-
Parexel to be Acquired by EQT Private Equity and Goldman Sachs Asset Management
7/2/2021
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund and the Private Equity business within Goldman Sachs Asset Management from Pamplona Capital Management LP for $8.5 billion.
-
Parexel Recognized as Most Favored Provider in ISR CRO Phase I Quality Benchmarking Report
5/13/2021
Recognition marks fourth consecutive year as top-ranked Phase I provider to work with; Company ranked among top-two global CROs for Service Provider Leadership, Familiarity, Use and Preference in Phase I
-
Parexel Completes Separation of Parexel Informatics and Medical Imaging Business
1/11/2021
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, announced it has completed the separation of its Parexel Informatics and Medical Imaging business.
-
Parexel Completes Purchase of Roam Analytics’ Natural Language Processing
9/22/2020
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced it has completed the purchase of the Natural Language Processing (NLP) technology assets and transfer of key personnel of Roam Analytics, Inc., a healthcare software company based in San Francisco, California. This strategic move will further stren
-
Parexel’s Deb Tatton Named to 2020 PharmaVOICE 10024-year Parexel veteran recognized as one of the 100 most inspiring people in life sciences for leadership of Parexel’s Global Clinical Operations
8/3/2020
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to market to improve world health, from Clinical through Commercialization, announced that Deb Tatton, Senior Vice President, Global Clinical Operations, has been named to the PharmaVOICE 100 list of the most inspiring people in the life sciences industry.